# Jim Cramer Says Johnson & Johnson Reflects Demand for Defensive Stocks

By Enna Lee

Canonical URL: https://www.tokenpost.com/news/investing/58758
Published: 2026-11-16T19:54:52.000Z
Updated: 2026-11-16T19:54:52.000Z
Section: Investing

> Health care and consumer staples led U.S. sectors over the past month, while technology stocks fell more than 9%.

Johnson & Johnson shares reached a new high Monday as defensive stocks outperformed, and Jim Cramer called the drugmaker a model of what investors are favoring as technology shares weakened.

Health care and consumer staples were the S&P 500’s strongest sectors over the past month, gaining 7% and 6%, respectively. The S&P 500 fell nearly 3% over the same period, while technology stocks lost more than 9%. Concerns about how the midterm election results might affect data center construction have weighed on technology stocks.

J&J closed at a record high Friday and reached another all-time high Monday before reversing lower. Its shares have gained 20% since early April. Monday’s advance followed the company’s announcement that it would acquire clinical-stage biopharmaceutical company Ollin Biosciences.

The agreement calls for $2.2 billion up front and up to $1.13 billion in additional payments if certain milestones are met. The deal will expand J&J’s treatments for serious eye diseases.

“[J&J] is a metaphor for what’s working,” Cramer said Monday. He also called J&J “the exact opposite of Nvidia,” describing it as a clean company that investors like.

J&J reported better-than-expected revenue and earnings for the third quarter last month, but its shares fell nearly 6%. Weakness in the MedTech segment and a tendency for the stock to trade poorly on earnings day weighed on the shares. Cramer said investors can overlook a company’s underlying results immediately after earnings, then recognize its strengths later.

Cramer has pointed to J&J’s drug pipeline, including its blood cancer treatments and Icotyde, an oral treatment for plaque psoriasis. J&J plans to spin off its orthopedics business by 2027 and is set to report fourth-quarter results next month.


